{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-22-003482","form_type":"8-K","ticker":"INKT","cik":"0001840229","company_name":"MiNK Therapeutics, Inc.","filed_at":"2022-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.749174+00:00","generated_at":"2026-06-25T21:59:45.990863+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"MiNK Q1 2022 net loss $7.8M ($0.23/share); cash $34.7M; clinical milestones on track","bullets":["Net loss $7.8M vs $3.8M YoY; per share loss $0.23 vs $0.16; non-cash expenses $813K.","Cash balance $34.7M at March 31, 2022; projected FY 2022 cash burn $16.8M.","R&D expenses $5.3M (+70% YoY) and G&A $2.1M (+253% YoY) due to increased activity.","Clinical data readouts for agenT-797 in solid tumors and ARDS on track for 2H 2022.","GMP manufacturing launch anticipated in 1H 2022 with target 10,000 doses/yr."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-22-003482","json":"https://secwatch.observer/filing/0001171843-22-003482.json","markdown":"https://secwatch.observer/filing/0001171843-22-003482.md","text":"https://secwatch.observer/filing/0001171843-22-003482.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840229/000117184322003482/0001171843-22-003482-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840229/000117184322003482/f8k_051022.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T21:59:45.990863+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}